首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   35篇
  免费   1篇
基础医学   1篇
临床医学   2篇
内科学   8篇
外科学   11篇
药学   6篇
肿瘤学   8篇
  2020年   1篇
  2018年   2篇
  2017年   1篇
  2016年   2篇
  2015年   1篇
  2013年   1篇
  2012年   3篇
  2011年   3篇
  2010年   2篇
  2009年   2篇
  2008年   1篇
  2007年   1篇
  2005年   1篇
  2002年   1篇
  1999年   1篇
  1998年   1篇
  1986年   1篇
  1982年   3篇
  1981年   3篇
  1980年   1篇
  1979年   1篇
  1978年   1篇
  1977年   1篇
  1972年   1篇
排序方式: 共有36条查询结果,搜索用时 15 毫秒
31.
The pharmacokinetic aspects of florfenicol (FLO) were investigated via intravenous (I.V.) and intramuscular (I.M.) injections in five goats at a dose of 20 mg kg−1 b.wt. Animals were pre-treated with albendazole orally in a dose of 2.5 mg kg−1 b.wt, ivermectin or rafoxanide subcutaneously in a dose 0.2 and 7.5 mg kg−1 b.wt, respectively. Florfenicol was injected intramuscularly two hours following anthelmentic administration and blood samples were taken by jugular venapuncture at standardized intervals. The concentrations of florfenicol (FLO) in serum were determined by high performance liquid chromatography (HPLC) method. The obtained results revealed that ivermectin administration did not induce a significant difference in serum florfenicol concentration between anthelmentic-treated and non-treated goats. On the other hand, goats pre-treated with rafoxanide or albendazole showed a significant decrease in serum florfenicol level as compared to non-anthementic treated goats. The absorption half-life (t½ab), Cmax, AUMC, AUC and systemic bioavailability (F%) are significantly decreased, whereas elimination half-life (t½el) and MRT are increased in goats pre-treated by the three tested anthementics.  相似文献   
32.
1 Histamine injection via the cannulated portal vein significantly raised the portal pressure in normal volunteers. This elevation was reversed by an H1-receptor blocker but not an H2-receptor blocker. When an H1-receptor blocker was injected first followed by histamine, no significant change in portal pressure was obtained. On the other hand, an H2-receptor blocker failed to antagonize the effect of histamine. 2 Histamine injection induced a non-significant increase in the portal pressure in patients with schistosomal portal hypertension, but when an H1-receptor blocker was injected a significant drop in the portal pressure was obtained. No similar effect was found after an H2-receptor blocker injection. 3 Angiographic study showed that histamine induced intrahepatic portal vasoconstriction in the normal controls. A similar change was obtained in the schistosomal group, particularly on the periportal neovascular formation. 4 In the light of the present study, it is suggested that histamine may contribute in part to the physiopathologic changes that lead to portal hypertension in hepatosplenic schistosomiasis. H1-receptor antagonists may have a role in the treatment of portal hypertension, particularly in bleeding varices.  相似文献   
33.
34.
1. Three groups of four clinically healthy buffaloes were injected with sulphadiazine, or sulphadimidine, or sulphathiazole in a single dose of 100 mg/kg body weight. 2. Changes in the serum enzyme activities (SGOT, SGPT and alkaline phosphatase) observed with the tested sulphonamides were insignificant, except for increases in SGOT level 6 h after sulphathiazole injection, and in GOT/GPT ratio 30 min and 24 h after sulphadimidine injection. 3. The creatinine level was not affected in sulphonamide-injected animals. All blood samples collected 15 min to 24 h after sulphathiazole injection showed marked increase in glucose and urea levels. Concerning the other two sulphonamides, no significant change was observed in these parameters except for an increased glucose level 24 h after sulphadiazine injection.  相似文献   
35.
OBJECTIVE: The purpose of this study was to test the hypothesis that explanted perfused arteries can serve as the initial endothelial cell culture source to evaluate the onset of angiogenesis in a cellulose acetate electrospun scaffold. METHODS: Electrospun scaffolds with fiber diameters roughly controlled in three broad ranges: 0.01 to 0.2, 0.2 to 1, and 1 to 5 microm (Nanomed Nanotechnol Biol Med 2:37-41, 2006), were used in cell culture to determine which provides the best culture topology. This scaffold was then tested in a bioassay chamber whose cellular source was an explanted abdominal aorta from donated euthanized mice. Scaffolds were draped over a cannulated vessel perfused for 24 h. Cell viability, density, and morphology were quantified. RESULTS: The largest fiber diameter group provided the best culture topology for human umbilical vein endothelial cells, showing high cell viability and density, and enhanced elongated cell morphology. Addition of single-walled carbon nanotubes decreased cell density significantly but chitosan heightened cell density and promoted spontaneous capillary tube like structure. Viability of endothelial cells increased with higher flow in the bioassay chamber. CONCLUSIONS: Endothelial cells showed a growth preference towards larger diameter fibers. Addition of chitosan improved culture conditions. Thus, this study provides a proof of principle for the possibility of co-culturing tissue engineered vascular networks from a perfused explant.  相似文献   
36.
Anorectal pressure in patients with symptomatic hemorrhoids   总被引:4,自引:4,他引:0  
This study was carried out on 30 patients with symptomatic internal hemorrhoids and 20 normal controls. The anal sphincter pressure was studied before and after surgery. A significantly high anal pressure was found in all patients with symptomatic internal hemorrhoids, when compared with normal controls, and there was no relation between this increase and the degree of hemorrhoids. One week following surgery, this high pressure was reduced significantly and was not affected by the type of operation. Thus, this increase in resting anal pressure is due to an overactivity of the internal hemorrhoids, which is secondary to the presence of the hemorrhoidal mass.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号